El área de moléculas para su uso en anticuerpos conjugados es nueva y posiciona a Pharmamar como proveedora de productos citotóxicos necesarios para las empresas especializadas en la tecnología de anticuerpos conjugados. Actualmente dos fármacos de este tipo ya comercializados facturaron en conjunto 1.300 millones de euros en 2017.
Tetrahydroisoquinolines in therapeutics : A patent review (2010-2015) .
Inder Pal Singh & Purvi Shah .
Introduction: 1,2,3,4-Tetrahydroisoquinoline (THIQ) is one of the “privileged scaffolds”, commonly found in nature. Initially, this class of compounds was known for its neurotoxicity. Later on, 1-methyl-1,2,3,4-tetrahydroisoquinoline was proved as an endogeneous Parkinsonism-preventing agent in mammals. The fused THIQs have been studied for their role as anticancer antibiotics. The US FDA approval of the trabectedin for the treatment of soft tissue sarcomas, is a milestone in the anticancer drug discovery.
Areas covered: This review covers the patents on various therapeutic activities of the THIQ derivatives in the years between 2010 and 2015. Patents were collected using a thorough search of Espacenet and WIPO databases. The therapeutic areas covered include cancer, malaria, central nervous system (CNS), cardiovascular, metabolic disorders, and so on. This also includes several patents on specific THIQs of clinical importance.
Expert opinion: A large number of the THIQ derivatives have been synthesised for various therapeutic activities, with noticeable success in the area of drug discovery for cancer and CNS. They may also prove to be promising candidates for various infectious diseases, such as malaria, tuberculosis, HIV-infection, HSV-infection, leishmaniasis, etc. They can also be developed as novel class of drugs for various therapeutic activities with unique mechanism of action.